Intraperitoneal vs systemic cisplatin in combination with systemic epidoxorubicin+ clophosphamide in advanced ovarian cancer patients with minimal residual disease after prior surgery: Update of a randomized study

MLA

Romanini, A., et al. Intraperitoneal vs Systemic Cisplatin in Combination with Systemic Epidoxorubicin+ Clophosphamide in Advanced Ovarian Cancer Patients with Minimal Residual Disease after Prior Surgery: Update of a Randomized Study. Jan. 1997. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3728..d40b3474684b7e7ba844227db80eaf27&authtype=sso&custid=ns315887.

APA

Romanini, A., Tanganelli, L., Gadducci, A., Brunetti, I., Bruzzone, M., Mammoliti, S., Carnino, F., & Conte, P. (1997). Intraperitoneal vs systemic cisplatin in combination with systemic epidoxorubicin+ clophosphamide in advanced ovarian cancer patients with minimal residual disease after prior surgery: Update of a randomized study.

Chicago

Romanini, A, L Tanganelli, Angiolo Gadducci, I Brunetti, M Bruzzone, S Mammoliti, F Carnino, and Pf Conte. 1997. “Intraperitoneal vs Systemic Cisplatin in Combination with Systemic Epidoxorubicin+ Clophosphamide in Advanced Ovarian Cancer Patients with Minimal Residual Disease after Prior Surgery: Update of a Randomized Study,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3728..d40b3474684b7e7ba844227db80eaf27&authtype=sso&custid=ns315887.